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Although many studies have assessed factors affecting culture conversion during tuberculosis treatment,
few have looked into the effect of tobacco smoking. This study included 89 active pulmonary tuberculosis
patients with positive sputum culture upon presentation and collected information regarding smoking
history and culture conversion after 60 days of therapy. Current smokers had a higher risk (OR 5.6; 95%CI
1.7e18.7) of non-conversion after two months of therapy when compared to never and ex-smokers.
Cavities on chest X-ray and alcohol abuse were shown to confound this association. After adjustment
for cavities on the chest X-ray and alcohol abuse current smoking compared to current non-smoking
remained signiﬁcantly associated with culture non-conversion at 60 days of treatment (adjusted OR
6.9; 95%CI 1.8e26.7, p ¼ 0.002) with a signiﬁcant (p ¼ 0.004) trend in adjusted OR with the number of
cigarettes smoked daily to 11.6 (1.8e73.4) among those smoking more than 20 cigarettes per day. In
conclusion tobacco smoking was found to delay culture conversion during treatment for pulmonary
tuberculosis in a dose-dependent manner. More research is needed to elucidate the effects of smoking on
tuberculosis treatment response, and of smoking cessation during tuberculosis treatment.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Tuberculosis (TB) is oneof theworld’s leading infectiousdiseases.
In 2010 there was an estimated 8.7 million incident cases and 1.4
million deaths from TB [1]. Tobacco use is a major public health
problem and an important preventable risk for premature deaths.
Extensive research has shown associations between tobacco smok-
ing andTB [2e5], and identiﬁedan increased riskofmortalityamong
smokers due to TB [6]. Smoking causes numerous pathophysiolog-
ical changes within the respiratory system, including immunolog-
ical effects, decreased clearance and altered adherence of inhaled
pathogens [7]. Tobacco smoking also impedes the pulmonaryth, Academic Medical Center,
s.
).
All rights reserved.expression of anti-TB T-helper type 1 (Th-1) immunity via inhibiting
innate immune activation and lung T-cell recruitment [8].
Adequate treatment of TB is essential to reduce morbidity and
mortality, and to prevent the spread of the disease [9,10]. Smoking
has been suggested to affect treatment outcome expressed as
mortality or as sputum smear conversion during treatment [11,12].
Few studies have assessed the effect of smoking on culture con-
version during treatment, and those that did yielded discordant
results [13e18]. An effect of smoking on the time to culture con-
version would be important since a delay in conversion may
translate into prolonged infectiousness and increased risk of
transmission to others. Furthermore persistent non-conversion
after 2 months of treatment can predict relapse after successful
treatment [19].
We therefore studied the effects of tobacco smoking on culture
conversion in a prospective cohort of patients on ﬁrst-line treat-
ment for pulmonary tuberculosis.
Figure 1. Proportion of patients with positive culture (non-conversion) after 2 months
of treatment, by smoking status. Vertical lines denote 95% conﬁdence intervals. Un-
adjusted odds ratios (95% conﬁdence intervals): ever smokers vs. never smokers 2.13
(0.56e8.13), p ¼ 0.378; current smokers vs. current non-smokers 5.63 (1.69e18.72),
p ¼ 0.004; current smokers vs. ex-smokers 11.79 (1.44e96.23), p ¼ 0.002.
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This study was part of a larger cohort study of TB treatment.
Eligible for enrollment were all patients consecutively diagnosed
with smear- and/or culture-positive pulmonary tuberculosis at two
specialized hospitals in Brazil (Santa Maria Hospital and the State
Institute of Chest Diseases Ary Parreiras) during the period March
2007 to September 2009. Included for the current analyses were all
patients who provided informed consent and for whom sputum
culture results were available before starting treatment and after 60
days of standardized ﬁrst-line TB treatment consisting of isoniazid,
rifampicin, pyrazinamide and ethambutol. Patients for whom the
pretreatment isolate showed resistance to isoniazid and rifampicin
(i.e. multidrug resistance) were excluded as these were likely to be
non-responsive to ﬁrst-line treatment. All were treated as in-
patients until they were no longer infectious.
Clinical and socio-demographic data were collected before
treatment and sputum samples were assessed at day 0 and after 60
days of TB treatment. Sputum samples were submitted to micro-
scopic examination of Ziehl-Neelsen stained smears. Samples were
then processed using the Kubica method and inoculated onto
Löwenstein-Jensen medium. Smears were graded in accordance to
theWHO guideline as 1þ, 2þ, 3þ, scanty and negative [20]. Patients
were classiﬁed as previously treated (i.e. with a history of use
of anti-tuberculosis drugs for more than one month) or new
(i.e. otherwise).
History of tobacco smoking was ascertained at entry by stan-
dardized, staff administered questionnaire as current smoking and
smoking in the past. Patients were grouped in twoways: as current
smokers versus current non-smokers (to reﬂect effects of smoking
during the months preceding the TB treatment on culture conver-
sion), and as ever smokers, i.e. current smokers or ex-smokers,
versus never smokers (to reﬂect cumulative effects of tobacco
smoke exposure on culture conversion). In addition, possible dosee
response effects were examined based on the number of cigarettes
currently smoked per day and the number of pack-years smoked
cumulatively.
Since patients with substance abuse may be less compliant to
therapy, drug and alcohol abuse were identiﬁed as potential con-
founders of the association between smoking and culture conver-
sion. For the classiﬁcation of alcoholism the CAGE criteria were
used [21]. Other potential confounders considered in the analysis
were HIV infection, sex, ethnicity, malnutrition, illiteracy, the
number of pulmonary cavities on chest X-ray, and pretreatment
smear microscopy results. Malnutritionwas deﬁned as a body mass
index (BMI) score below 18.5 kg/m2 [22]. Because there were only
two patients with diabetes mellitus, this potential confounder was
not included in the analysis.
Data were stored electronically and analyzed using Statistical
Package for Social Science 13.0 (IBM Corp, Armonk NY, USA). Odds
ratios (ORs) with their 95% conﬁdence interval (95%CI) were
calculated for the associationwith culture conversion, and p-values
were obtained using the two-sided Fisher’s exact test. We checked
all covariates for potential confounding of the association between
smoking history and culture conversion by bivariate logistic
regression. Included in the ﬁnal multivariable logistic regression
model were those covariates that changed the OR for this associ-
ation (i.e. displayed confounding) by more than 10%. All tests were
done at the 5% signiﬁcance level.
3. Results
The study enrolled 164 patients, of whom 104 (63.4%) had non-
MDR TB and follow-up data at day 60 available. Pretreatment cul-
ture results were missing for another 12 (11.5%) patients, and day-60 culture results were missing for 1 (0.9%) patient. In addition, 2
(1.9%) patients were excluded because of missing smoking infor-
mation (Figure 1).
The remaining 89 patients were included in the analysis
(Table 1). Of these 76 (85.4%) were males; 23 (25.8%) were never-
smokers, 43 (48.3%) current smokers and 23 (25.8%) ex-smokers.
All current and ex-smokers smoked cigarettes.
At 60 days of treatment, 19 patients (21.3%) remained culture
positive and 70 (78.7%) had culture conversion.
The odds for culture non-conversion at 60 days of treatment
were signiﬁcantly increased for current smokers compared to
current non-smokers (odds ratio (OR) 5.63; 95% conﬁdence interval
(95%CI) 1.69e18.72): 15 of 43 (34.9%) current smokers had no
culture conversion versus 4 of 46 (8.7%) current non-smokers
(p ¼ 0.004). Similarly, the odds for culture non-conversion at 60
days of treatment were signiﬁcantly increased for current smokers
compared to ex-smokers (OR 11.79, 95%CI 1.44e96.23, p ¼ 0.002,
Figure 1), but not for ever-smokers compared to never-smokers (OR
2.13, 95%CI 0.56e8.13, p ¼ 0.378). There was a signiﬁcant trend in
probability of culture non-conversionwith the number of cigarettes
smoked daily among current smokers from 27.3% for 1e19 ciga-
rettes (less than one package) and 35.0% for 20 cigarettes (one
package) to 41.7% for >20 cigarettes (more than one package;
p ¼ 0.003). No clear trend was observed for the number of pack-
years smoked (Figure 2).
The only other signiﬁcant predictor of culture non-conversion
at 60 days of treatment was the smear result at baseline
(Supplement). In addition to smear test result, the number of
cavities, alcohol abuse, malnutrition, and illicit drug use
confounded the association between smoking and culture con-
version in the bivariate analyses (Supplement). In the multivar-
iable model, only the number of cavities and alcohol abuse
remained as confounders. After adjustment for alcohol abuse and
number of cavities, current smoking compared to current non-
smoking remained signiﬁcantly associated with culture non-
conversion at 60 days of treatment (adjusted OR 6.85; 95%CI
1.76e26.70, p ¼ 0.002). Compared to current non-smokers, the
adjusted OR for non-conversion increased signiﬁcantly with the
number of cigarettes smoked daily from 4.2 for 0e19 cigarettes
to 7.9 for 20 cigarettes and 11.6 for >20 cigarettes (p ¼ 0.015;
trend across categories p ¼ 0.004; Table 2). There were no sig-
niﬁcant interactions. Adding the number of pack years (>10
years versus 10 years) to this model did not result in signiﬁ-
cantly improved prediction of culture conversion (adjusted OR
0.76, p ¼ 0.743).
Table 1
Baseline characteristics of 89 patients with culture-positive pulmonary tuberculosis.
Characteristic n. (%)
Sex Female 13 (14.6)
Male 76 (85.4)
Ethnicity Non-African descent 31 (34.8)
African descent 27 (30.3)
Mixed African descent 25 (28.1)
NA 6 (6.7)
Literacy Illiterate 14 (15.4)
Literate 75 (82.4)
Smoking Never 23 (25.8)
Current 43 (48.3)
Ex-smoker 23 (25.8)
Alcohol abuse (CAGE) No 29 (32.6)
Yes 59 (66.3)
NA 1 (1.1)
Illicit drug use No 62 (69.7)
Yes* 27 (30.3)
Diabetes mellitus No 76 (85.4)
Yes 2 (2.2)
NA 11 (12.4)
Previously treated for TB No 50 (56.2)
Yes 36 (40.4)
NA 3 (3.4)
HIV infection status Negative 73 (82.0)
Positive 13 (14.6)
NA 3 (3.4)
Body mass index (BMI)
at start of treatment
18.5 kg/m2 24 (27.0)
<18.5 kg/m2 56 (62.9)
NA 9 (10.1)
Findings chest X-ray
Reduced volume Yes 36 (40.4)
No 53 (59.6)
Increased volume Yes 16 (18.0)
No 73 (82.0)
Inﬁltrates Yes 18 (20.2)
No 71 (79.8)
Nodules Yes 3 (3.4)
No 86 (96.6)
Cavities 0 16 (18.0)
1e2 40 (44.9)
3e4 33 (37.1)
Culture conversion Yes 70 (76.9)
After 2 months of treatment No 19 (21.4)
NA: not available.
* Includes 18 (20.2%) patients who smoked illicit drugs.
Figure 2. Proportion of patients with positive culture (non-conversion) after 2 months
of treatment. A. By average number of packages of cigarettes currently smoked par day.
Cuzick’s non-parametric test for trend: p ¼ 0.003. B. By number of pack-years of
cigarette smoking. Cuzick’s non-parametric test for trend: p ¼ 0.147.
Table 2
Multivariable logistic regression model for the association between current smoking
and culture conversion at 60 days of anti-tuberculosis treatment.
Variable Category Adjusted odds ratio
(95% conﬁdence interval)
p-value
Current tobacco smoking*:
daily number of cigarettes
0 1 0.015
1e19 4.22 (0.72e24.94)
20 7.89 (1.59e39.08)
20 11.57 (1.82e73.42)
Alcohol abuse No abuse 1 0.027
Abuse 0.22 (0.05e0.90)
Cavities Numbery 2.30 (0.96e5.54) 0.050
* p-value for trend (ﬁtted as linear variable) 0.004. Current smoking versus no
current smoking: adjusted odds ratio 6.85 (95%CI 1.76e26.70), p ¼ 0.002.
y Average odds ratio for each additional cavity.
R. Nijenbandring de Boer et al. / Tuberculosis 94 (2014) 87e91 894. Discussion
This prospective cohort study of pulmonary TB patients found a
strong and independent association between current smoking and
a positiveMycobacterium tuberculosis culture at 60 days of standard
ﬁrst-line treatment. There was a signiﬁcant dose-response rela-
tionship with the number of cigarettes smoked daily. No such as-
sociation was found for ever smoking compared to never smoking,
nor for the number of pack-years as an indicator of cumulative
exposure to tobacco smoke.
Two previous studies showed an association between a history
of ever smoking and delayed culture conversion during treatment
[13,14], while three others gave ambiguous results [15e17]. Ever
smokers compared to never smokers had signiﬁcantly longer time
to conversion in a randomized-controlled therapeutic vaccination
trial and in a cohort study, both conducted in South Africa (adjusted
hazard ratio for conversion 0.58 and 0.45, respectively) [13,14].
However, neither routine data from Hong Kong nor a cohort study
from Turkey showed delayed culture conversion for ever smokers
[15,16], and in a multi-country, randomized-controlled drug trial
culture conversion at two months was associated with ever
smoking in univariate, but not in multivariate analysis [17]. Only
one study speciﬁcally assessed the effect of current smoking: acase-control study from Brazil found the risk of culture positivity at
two months of therapy to be 3-fold increased for current smokers
compared to non-smokers, and in addition 2-fold increased for
smoking >20 cigarettes per day [18].
Taken together with our results this suggests that it is in fact
current smoking that deﬁnes the effect of smoking on culture
conversion, that different proportions of current smokers among
the ever smokers may explain the contradicting results from pre-
vious studies, and that cumulative lung damage due to smoking
seems to be less relevant. This would support the hypothesis that
immunological changes caused by smoking interfere with anti-
tuberculosis treatment.
Several studies found that higher pretreatment sputum smear
grades, cavitary disease and/or prior history of TB predict delayed
culture conversion [12,14,16,18].We found similar associations with
60-day culture conversion, although this was statistically signiﬁ-
cant only for smear grade, probably due to the relatively small size
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number of cavities confounded the association between smoking
and culture conversion, which may reﬂect that smokers with TB
more frequently have cavities [23]. The effect of current smoking on
60-day culture conversion remained after multivariable adjust-
ment, indicating that this is independent of the extent of disease
and residual lung damage due to earlier TB episodes. A previous
study reported delayed smear conversion in association with
smoking only among patients with extensive TB disease deﬁned by
radiological criteria and initial smear grade [12]. We found no such
interactions for culture conversion but the power of our study to
detect these as statistically signiﬁcant was small.
Also alcohol abuse confounded the association between smok-
ing and culture conversion, but contrary to previous studies pa-
tients who abused alcohol had a tendency towards higher
probability of culture conversion by day 60. The available literature
suggests that alcohol abuse predisposes for a poor response to anti-
tuberculosis treatment [24], is linked to poor compliance to therapy
[25,26], and therefore, by taking fewer than prescribed drug doses,
results in a higher risk of non-conversion [4]. Possibly the patients
with alcohol abuse in the present study were monitored more
strictly for taking their medication. This can only be speculated, as
we did not collect information about treatment adherence. How-
ever the whole study population was treated as in-patients, which
would make non-compliance less plausible. As the results may be
contradictory to the literature, the possibility of uncontrolled con-
founding has to be considered. Alcohol abuse was deﬁned using the
CAGE criteria at the start of therapy and no additional information
was available concerning the duration and degree of alcohol de-
pendency as identiﬁed by other instruments such as the Michigan
Alcohol Screening Test [27]. and therefore this possibly important
distinction could not be made. Instead there might be a biological
explanation to the association between alcoholism and non-
conversion, which smoking possibly emphasizes.
Two partially related hypotheses may explain the delayed cul-
ture conversion among current smokers. One could be the altered
activity of nitric oxide (NO). NO is an important effectormolecule in
the defense against intracellular organisms [28]. Activated macro-
phages that are capable of suppressing multiplication of, or killing,
M. tuberculosis express nitric oxide synthase (NOS) which is
essential for the production of NO; its anti-microbial activity was
lost when NOS inhibitors were present [28]. Cigarette smoking is a
NOS inhibitor and its irreversible inhibitory effect has been shown
in pulmonary endothelial cells [29]. Another hypothesis is altered
iron content of alveolar macrophages. In addition to its anti-
microbial properties, NO is an important regulator of iron meta-
bolism [30]. When iron levels become excessive, NO interacts with
ironesulfur clusters in enzymes to generate toxic radicals that may
damage intracellular proteins leading to a loss of function of acti-
vated macrophages including growth control of M. tuberculosis
[30,31]. The iron content of bronchoalveolar macrophages of
smokers was shown to be at least twice that of non-smokers [31],
with the higher iron load likely to come from cigarettes. As reported
by Thompson et al., smoking one pack per day presents 1.12 mg of
iron [32]. If cigarette smoking hinders host-defense by inhibition of
NO production and the production of toxic radicals, then it is
plausible that smoking delays clearance of multiplying bacilli and
thereby culture conversion.
Our study had a number of strengths. It was prospective, all
patients were treated as in-patients and we collected detailed in-
formation on clinical and behavioral factors that might underlie
associations between smoking and culture conversion.
It also had limitations. The sample size was small, and only 19
patients had delayed conversion. Although we found strong and
signiﬁcant associations, this small sample size might have limitedthe statistical power of ﬁnding relevant interactions with e.g.
extent of disease. Smoking histories are subject to recall bias and
we did not collect details about the type of cigarettes smoked and
possible cessation periods. Patients who smoked very little might
have considered themselves as non-smokers, others might have
cited wrongly the number of cigarettes smoked daily in the past. As
it is known to cause preventable health problems, smoking might
be subject to stigmatization, leading some patients to answer un-
truthfully about their smoking behavior. Our smoking data were
collected before treatment and we did not have information about
smoking cessation during treatment. Additionally, no information
was collected on the persistent use of solid fuel sources in the
homes.
Finally, ours was a rather selected study population of mainly
disadvantaged TB patients with high levels of alcoholism, drug
abuse and malnutrition. Even though we made adjustments in our
analyses for possible confounding effects caused by these charac-
teristics, this study population may not be fully representative of
other TB patients with regard to the effect of smoking on treatment
response.
In conclusion, pulmonary TB patients who smoked at the start of
standard ﬁrst-line treatment were found to have delayed response
to therapy based on M. tuberculosis culture results after 2 months
compared to non-smokers or ex-smokers. Therefore, smokers likely
have prolonged infectiousness, and together with the higher ten-
dency for cough, may give rise to increased risks of transmission
during the initial phase of treatment. Further research is needed to
understand the mechanisms that underlie the effect of smoking on
the response to anti-TB treatment as well as the impact of smoking
cessation during tuberculosis treatment.
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